Search results
Results from the WOW.Com Content Network
Mapp Biopharmaceutical develops novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on global health and biodefense.
Mapp Biopharmaceutical was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...
ZMapp® is the result of a collaboration between Mapp Biopharmaceutical, Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC). ZMapp® is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana.
Kevin Whaley – CEO. Kevin Whaley has worked for the last 30 years on the development of multipurpose prevention technologies (MPTs), i.e. products that simultaneously prevent sexually transmitted diseases and unwanted pregnancy. He co-founded Mapp to develop antibody-based MPTs, therapeutics and mucosal vaccines that are appropriate for large ...
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...
What is ZMapp®? ZMapp® is an experimental new therapy that is being developed to treat patients with Ebola. It is comprised of a series of three different monoclonal antibodies that work to prevent the spread of the disease within the body.
The Administration for Strategic Preparedness and Response (ASPR) today announced a $109.8 million contract with Mapp Biopharmaceutical Inc., for the advanced development and potential purchase of a monoclonal antibody therapeutic to treat Sudan ebolavirus (SUDV).
These antibodies have demonstrated unprecedented therapeutic efficacy in non-human primate models of Sudan virus infection with only a single dose. Mapp has obtained an exclusive license to develop and commercialize these antibodies from Adimab and Einstein.